semaglutide step 5 Weight regain and cardiometabolic effects after withdrawal of semaglutide: The 1 trial extension - Wilding - 2022 - Diabetes, Obesity and Metabolism Echocardiography substudy of the STEP-#HFpEF

11 In April 2026 the FDA removed BPC-157 (along with several other peptides) from that interim list, but it is important to read that move correctly: it was a procedural step tied to withdrawn nominations and a fresh review under the Section 503A framework, not a finding that the compound is safe or effective, and it did not add BPC-157 to the positive list of substances sanctioned for compounding

doi: 10.1126/science.adt0548 66 YangJ.HuS.BianY.YaoJ.WangD.LiuX.et al

Modulating ion channel activity provides a powerful means of influencing neuronal behavior, offering potential therapeutic avenues for a wide range of neurological and psychiatric disorders ( Ca 2 + ions serve as vital second messengers, regulating key cellular processes such as neurotransmitter release and gene expression (Pikor et al., 2024)

What happens when medication is discontinued: Studies show most people regain some or all weight lost when stopping therapy, suggesting a life-long reliance to maintain results

These usually resolve with slow dose titration